ONESOURCE · Healthcare
Onesource Specialty Pharma Ltd. reported revenue of ₹334 cr for July to September 2024, +882.4% on the year and +14.4% on the quarter.
Operating profit (EBITDA) was ₹77.0 cr, a margin of 23.1%, +13,776 bps on the year and +114 bps on the quarter.
The net loss was ₹42.0 cr.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
Finance cost rose fast and now takes a large bite of operating profit. New borrowing, or a higher rate?
Finance cost ₹45.0 cr, +80.0% on the year; 58% of EBITDA.
Source: Quarterly statements
Could not run on this quarter: Headline vs core profit, Other income carrying profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹56.0 cr | ₹73.0 cr | ₹292 cr | ₹334 cr | ₹393 cr | ₹426 cr | ₹327 cr | ₹376 cr | ₹290 cr | ₹428 cr | ₹449 cr | ₹516 cr |
| YoY | — | — | — | +882% | +602% | +484% | +12% | +13% | −26% | +0% | +37% | +37% |
| EBITDA margin | −17.9% | −4.1% | 21.9% | 23.1% | 36.1% | 43.0% | 26.9% | 28.2% | 5.9% | 21.5% | 27.4% | 31.6% |
| Other income, % of PBT | — | — | — | — | — | 2% | — | 50% | — | — | 0% | −2% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | — | — | — | — | — | −19% | — | — | — | — | −23% | −9% |
| Net profit | −₹130 cr | −₹40.0 cr | −₹6.0 cr | −₹42.0 cr | −₹69.0 cr | ₹98.0 cr | ₹0.0 cr | ₹10.0 cr | −₹89.0 cr | ₹5.0 cr | ₹25.0 cr | ₹57.0 cr |
| YoY | — | — | — | — | — | — | — | — | — | −95% | — | +470% |
| Core profit YoY | — | — | — | — | — | — | — | — | −437% | −102% | — | +1,700% |
| EPS | — | — | — | — | −₹6.02 | ₹8.61 | −₹0.02 | ₹0.92 | −₹7.74 | ₹0.40 | ₹2.18 | ₹5.01 |
| Flags | · | · | · | 1 | 1 | 2 | ✓ | 2 | 1 | 1 | 1 | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Onesource Specialty Pharma Ltd. reported revenue of ₹334 cr (+882.4% on the year) and net profit of −₹42.0 cr (— on the year) for July to September 2024.
1 check raised a question: Finance cost rose fast and now takes a large bite of operating profit. New borrowing, or a higher rate?
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.